-
Featured
Immunotherapies to Treat Glioblastoma
William T. Curry, MD, co-director of Mass General Neuroscience and director of Neurosurgical Oncology in the Department of Neurosurgery at Massachusetts General Hospital, discusses a four-center trial studying the use of poliovirus to treat malignant brain tumors.
-
Revolutionizing Cancer Immunotherapy for Melanoma and Beyond
Researchers at Massachusetts General Hospital won a Breakthrough Award to enhance personalized approaches to immunotherapy for metastatic melanoma.
-
Review: The Role of Antibody-Based Therapies in Neuro-Oncology
Rishab Ramapriyan, William T. Curry, MD, Bryan D. Choi, MD, PhD, and colleagues describe the antibody-based therapies being used to treat glioblastoma and other central nervous system tumors, with special attention to the challenges of blood–brain barrier penetration and tumor-derived immunosuppression.
-
Concurrent Immunosuppressive Therapy With Restart of Checkpoint Inhibitor Reduces Risk of Recurrent Immune-related Enterocolitis
A retrospective study at Massachusetts General Hospital and two other centers found cancer patients who had an immune checkpoint inhibitor restarted after an episode of immune-related enterocolitis had significantly less risk of severe recurrent enterocolitis if they concurrently received infliximab or vedolizumab.
-
Review: Checkpoint Inhibitors and Other Immunotherapies in Urologic Cancer
Aleksandra Walasek, MD, and Dimitar V. Zlatev, MD, discuss progress in immunotherapies for urologic cancers, showing checkpoint inhibitors are often first-line therapy, combination regimens are improving outcomes, and antibody–drug conjugates are becoming new options for dual-refractory bladder cancer.
-
Activating CD4+ T Cells at Benign Nevi Might Prevent Melanoma
Shadmehr Demehri, MD, PhD, Erik B. Schiferle, and colleagues determined benign nevi harbor CD4+ T cells that can be activated in situ to reject the nevus. If a novel therapy could block immunosuppressive regulatory T cells, CD4+ cells might prevent progression to melanoma in high-risk patients and enhance immunotherapy.
Mass General Cancer Center Contributors
-
Areej R. El-Jawahri, MD
Hematologist, Mass General Cancer Center, Assistant in Medicine, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School
Recent Article
Enasidenib Safe, Well Tolerated As Maintenance After Stem Cell Transplantation for IDH2-Mutated Myeloid Malignancies
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
-
Justin Gainor, MD
Director, Center for Thoracic Cancers Program, Director of Targeted Immunotherapy, Mass General Cancer Center, Associate Professor of Medicine, Harvard Medical School
Recent Article
Molecular Features Identified That Predict Response to Checkpoint Inhibitors in NSCLC
-
Michael L. Dougan, MD, PhD
Physician, Division of Gastroenterology, Massachusetts General Hospital, Director, GI Center for Cancer Complications, Mass General Cancer Center, Preclinical Education Group Leader, Associate Professor of Medicine, Harvard Medical School
Recent Article
Case Series: Tofacitinib Is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology, Massachusetts General Hospital, Adeline Rose Wydotis Professor of Neurosurgery, Harvard Medical School
Recent Article
Review: The Role of Antibody-Based Therapies in Neuro-Oncology
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
